Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
Palisade Bio, Inc. recently announced the completion of patient enrollment in its dose optimization study of LB1148.
“Achieving our enrollment target in this study is an important milestone for our LB1148 clinical program,” said J.D. Finley, Chief Executive Officer of Palisade Bio. “Importantly, we remain on track for the Phase 2 topline data readout for the prevention of post-surgical abdominal adhesions in the coming weeks. The data from these two studies will provide meaningful information related to our future clinical development of LB1148.”
The dose optimization study was designed to generate valuable pharmacokinetic and pharmacodynamic data across multiple doses in healthy adult volunteers and to determine if a different dosing protocol might enhance the risk profile while simultaneously providing efficacy for the development program moving forward.
Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The company utilizes more than 3 decades of research and established science that links the role of intestinal barrier biology with human disease to advance novel therapeutics that target and improve the integrity of the intestinal barrier.
The company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, potentially reducing intestinal damage. In prior clinical studies, LB1148 has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially reducing the time to return of postoperative bowel function. LB1148’s current US Phase 2 study is evaluating its effectiveness in reducing intra-abdominal adhesions, accelerating return of gastrointestinal function, and the prevention of post-operative ileus in subjects undergoing elective bowel resection (PROFILE).
The company believes addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care. For more information, visit www.palisadebio.com.
Total Page Views: 819
